

MGI Tech, JCBio to advance multi-omics innovation in South Korea

02 September 2025 | News

Under the DCS Lab Project, JCBio is empowered to implement innovative sequencing strategies



MGI Tech, a company dedicated to developing core tools and technologies that drive innovation in life sciences, and JCBio Co., a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, a landmark collaboration.

The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI's advanced omics technologies with JCBio's local expertise, the partnership empowers researchers and clinicians while strengthening South Korea's role as a regional leader in genomics and biotechnology.

In an era where multi-omics research is reshaping healthcare, the collaboration between MGI Tech and JCBio marks a significant milestone in strengthening South Korea's genomics ecosystem. By combining MGI's proprietary short-read and long-read sequencing technologies, the initiative equips JCBio's laboratories with end-to-end multi-omics capabilities, enabling researchers to tackle complex biological challenges with greater precision and efficiency.

Under the DCS Lab Project, JCBio is empowered to implement innovative sequencing strategies, advance integrated multi-omics analyses, explore novel sequencing applications, accelerate precision medicine, clinical translation, and AI-driven data insights—positioning the laboratory as a local hub for cutting-edge genomic research and multi-omics innovation.

Launched in 2023, MGI's DCS Lab Initiative was established to empower international laboratories with comprehensive sequencing solutions. Named after MGI's three core technologies—DNA genomics, Cell omics, and Spatial omics—the DCS Lab initiative is the company's first global program targeting international laboratories with a focus on frontier science. It represents MGI's unique capability within the industry to provide end-to-end products for applications ranging from DNA genomics to cell omics and spatial omics.

The initiative has already enabled pioneering research worldwide. At MGI's Customer Experience Centre (CEC) in Australia, technologies such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have driven breakthroughs in cancer, medicine, and agriculture. Building on this success, MGI is now extending the programme to South Korea in collaboration with JCBio—reinforcing the nation's role as a key hub in Asia's rapidly growing biotech ecosystem.